Last update 21 Nov 2024
MSB-0254
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with MSB-0254评估MSB0254注射液在晚期实体瘤患者中的安全性和耐受性及药代动力学的一期临床试验
[Translation] A Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics of MSB0254 injection in patients with advanced solid tumors
Phase I Clinical Trial to Evaluate the Safety and Tolerability and Pharmacokinetics of MSB0254 Injection in Patients With Advanced Solid Tumors
100 Clinical Results associated with MSB-0254
Login to view more data
100 Translational Medicine associated with MSB-0254
Login to view more data
100 Patents (Medical) associated with MSB-0254
Login to view more data
1
Literatures (Medical) associated with MSB-025401 May 2022Biochemical and Biophysical Research CommunicationsQ3 · BIOLOGY
Anti-VEGFR2 monoclonal antibody(MSB0254) inhibits angiogenesis and tumor growth by blocking the signaling pathway mediated by VEGFR2 in glioblastoma
Q3 · BIOLOGY
Article
Author: Zhou, Youxin ; Li, Xuetao ; Chen, Sansong ; Wang, Hao ; Chen, Guangliang
100 Deals associated with MSB-0254
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Phase 2 | CN | - | |
| Advanced Malignant Solid Neoplasm | Preclinical | CN | 01 Apr 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 22 | algoieoxmh(tblrxnflnz) = One DLT was reported in 12mg/kg Q2W dose cohort. A subject with intra-cholangial carcinoma developed G3 (grade 3) upper gastrointestinal hemorrhage on the C1D13. The adverse event was resolved after symptomatic treatment. lrnmvjftad (gocprsmwad ) View more | Positive | 02 Jun 2022 | |||
Phase 1 | 19 | (yfkancsypt) = 高血压 6例（31.6%），中性粒细胞计数降低、γ-谷氨酰转移酶升高 和天门冬氨酸氨基转移酶升高各4例（21.1%），白细胞计数 降低、血小板计数降低、蛋白尿和贫血各3例（15.8%），上 消化道出血、牙龈出血和血尿症各2例（10.5%） xttbzdnrmo (zaenbxchmd ) View more | Positive | 25 Sep 2021 | |||
Phase 1 | 16 | (pckixjrgix) = tmhleqbkgo bxbkojlmbr (zfzrougkpg ) | - | 25 Sep 2021 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free